Cuban therapeutic vaccine CIMAVAX EGF, produced at the Molecular Engineering Center, started a new clinical trial against lung cancer in policlinics all throughout the country.

During the 3rd Provincial Workshop on Clinical Trials underway in Camaguey, Geidy Lorenzo promoter of the tests at the institution explained that the objective is to standardize and regulate the administration of the vaccines in the level of primary health care attention.

Its low toxicity, minimum occurrence of adverse effects and the its easy application allows for the vaccine to be supplied to health centers close to the patients like the policlinics and the family doctors office, said the specialist.

She pointed out that the trials have already gotten underway in at least one policlinic to a municipality in the provinces of Villa Clara and Havana and will gradually be extended to the rest of the country during 2016.

The coordinator in Villa Clara, Dr. Ramon Ortiz commented that the use of the therapeutic vaccine is complementary to other conventional therapies like radio and chemo.

The vaccines do not prevent or cure lung cancer, but contributes in controlling the illness and offers a better quality of life for the patients, above all when the tumor is at an advanced stage, said the specialist.

CIMAVAX EGF, that strengthens the immune system, obtained its first registry in Cuba in 2008 and is part of basic medication since 2012.

The vaccine has been administered to over three thousand patients in the country and is currently in clinical testing in other countries against lung tumors which is one of the main causes of death worldwide. / CNA.